Search Market Research Report
Irritable Bowel Syndrome (IBS) Diagnostics Market Size, Share Global Analysis Report, , 2021 – 2026
Irritable Bowel Syndrome (IBS) Diagnostics Market By Type (IBS-C, IBS-D and Mixed IBS), By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, & Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), And By Regions – Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2026
Industry Insights
[175+ Pages Report] The latest report published by facts and factors titled “irritable bowel syndrome (IBS) diagnostics market” has a global perspective on the latter coupled with the market size, volume, drivers, and restraints to name a few. We estimate that the global irritable bowel syndrome (IBS) diagnostics market will hold a value of USD 2.3 Billion by 2026 with a CAGR growth of 9.7% which was previously subjected at USD 1.2 Billion in the year 2020.
Market Overview
Irritable bowel syndrome is a disorder that targets the gastrointestinal tract causing the patients to suffer from a range of symptoms such as extreme discomfort in the stomach, diarrhea, cramping, and constipation, among others. IBS usually can occur over prolonged periods of diarrhea (gastroenteritis) which is caused by the presence of bacteria in the bowels. Early signs of IBS can range from lactose intolerance and breathe tests regarding bacterial overgrowth and can be fairly diagnosed by blood and stool sample tests. Advanced IBS can be detected by CT scans or X-rays, upper endoscopies, and colonoscopy.
Industry Growth Factors
The global irritable bowel syndrome diagnostics market is heavily driven by factors governing a higher prevalence of targeted diseases coupled with increased uptake of drugs during the forecast. Additional factors include a rise in the commercialization of existing product lines spread across various regions will further propel the growth of the market. Increased approval of linzess on a global scale will open new opportunities for the market to recoup revenue and improve sales. Improved testing methods and reliable treatment measures will further drive market growth. Moreover, an advent increase in factors pertaining to increased food allergies, predominant development of gastroenteritis, sporadic movements of the colon, the irregular composition of serotonin in the colon, and a rise in celiac diseases among the aging and advanced population will further boost the demand for IBS diagnostics over the projected forecast.
Increased awareness among consumers and manufacturers alike is expected to boost the growth of the irritable bowel syndrome (IBS) diagnostics market towards a large footprint. Collaborative efforts of global and local organizations are proving to be highly fruitful for a larger group of consumers to be made aware of IBS. An increased number of approved products from regulatory bodies across the globe open new market avenues for the IBS diagnostics market to flourish. However, lack of proper knowledge among consumers and unconfirmed diagnosis prescribed by similar practitioners is expected to constrain the growth of the market to a certain extent.
 Diagnostics Market.png)
Segmentation Analysis
The global irritable bowel syndrome (IBS) diagnostic market can be segmented into type, product, distribution channel, and regions.
The global irritable bowel syndrome (IBS) diagnostic market can be divided into ISB-C, ISB-D, and Mixed IBS on the basis of type. The IBS-C can be further broken down into linzess/constella, amitiza, and others and the IBS-D can be broken down into xifaxan, viberzi, and others. The cholera-predominant category is expected to witness the largest market share during the advent of the forecast owing to factors pertaining to rising uptake of drugs in the form of linzess/constella and amitiza. The segment of diarrhea-predominant category is expected to witness the fastest growing CAGR during the forecast owing to launches of various products which show high promises under clinical trials.
The global irritable bowel syndrome (IBS) diagnostics market can be fragmented into rifaximin, eluxadoline, lubiprostone, linaclotide, and others on the basis of product. The segment pertaining to rifaximin is expected to witness the largest market share during the forecast owing to various contributing factors such as the increasing prevalence of IBS among the geriatric population, increase in consumer awareness, effective diagnosis, and development of advanced processes. The global irritable bowel syndrome (IBS) diagnostics market can be broken down into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies on the basis of distribution channels.
Report Scope
Report Attribute |
Details |
Market Size in 2020 |
USD 1.2 Billion |
Projected Market Size in 2026 |
USD 2.3 Billion |
CAGR Growth Rate |
9.7% CAGR |
Base Year |
2020 |
Forecast Years |
2021-2026 |
Key Market Players |
Allergan, Astellas Pharma, Inc., Takeda Pharmaceuticals Company Limited, AstraZeneca, Sebela Pharmaceuticals, Inc., Synergy Pharmaceuticals, Banusch Health, Synthetic Biologics, Inc., Ardelyx, Johnson & Johnson, and Novartis AG, among others. |
Key Segment |
By Type, By Product, By Distribution Channel, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Regional Analysis
North America is expected to witness the largest market share during the forecast period in terms of global revenue collection. The presence of key players in the region along with advancements in technology detecting IBS will propel the region to hold a dominant position in the market. Additional factors fuelling the growth of the market can be contributed to the factors such as rising patient awareness and increased consumer spending targeted toward Diagnostics testing. Europe further accounts for a significant share in the market in terms of volume and sales followed by the region of Asia-Pacific. Growing population suffering from IBS and rising incentives are a common trend observed across the significant growth of the IBS Diagnostics market across both regions.
Competitive Players
The key participants in the global irritable bowel syndrome (IBS) diagnostics market are :
- Allergan
- Astellas Pharma Inc.
- Takeda Pharmaceuticals Company Limited
- AstraZeneca
- Sebela Pharmaceuticals Inc.
- Synergy Pharmaceuticals
- Banusch Health
- Synthetic Biologics Inc.
- Ardelyx
- Johnson & Johnson
- Novartis AG
By Type Segment Analysis
- ISB-C
- Linzess/Constella
- Amitiza
- Others
- ISB-D
- Xifaxan
- Viberzi
- Others
- Mixed IBS
By Product Segment Analysis
- Rifaximin
- Eluxadoline
- Lubiprostone
- Linaclotide
- Others
By Distribution Channel Segment Analysis
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Regional Segment Analysis
- North America
- U.S.
- Canada
- Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of MEA
Table of Content
Industry Major Market Players
- Allergan
- Astellas Pharma Inc.
- Takeda Pharmaceuticals Company Limited
- AstraZeneca
- Sebela Pharmaceuticals Inc.
- Synergy Pharmaceuticals
- Banusch Health
- Synthetic Biologics Inc.
- Ardelyx
- Johnson & Johnson
- Novartis AG
Copyright © 2023 - 2024, All Rights Reserved, Facts and Factors